X4 Pharmaceuticals, Inc. (XFOR) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The EV/EBITDA price chart for X4 Pharmaceuticals (XFOR) is fixed at 0.00. The business relies on a robust cold chain logistics system and global partners. X4 Pharmaceuticals (XFOR) develops oral agents to correct receptor function in WHIM syndrome. High scalability is embedded in the release of Xolremdi, where low capsule production costs are combined with exclusive pricing power in the orphan drug market.
x4pharma.com - analytical breakdowns and key metrics (XFOR)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity X4 Pharmaceuticals|XFOR - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital X4 Pharmaceuticals, Inc.|XFOR - Company Cumulative Debt|Debt to Book Value X4 Pharmaceuticals, Inc|XFOR - Company Long-Term Indebtedness|Company Short-Term Indebtedness X4 Pharmaceuticals|Intermediate Coverage Ratio x4pharma.com
- business earnings and investment ratios data:
XFOR - Company Net Income|Forward Earnings X4 Pharmaceuticals|XFOR - P/E Multiple|Future Price to Earnings Multiple X4 Pharmaceuticals|XFOR - PEG Multiple|EV/EBITDA Multiple X4 Pharmaceuticals, Inc|XFOR - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year X4 Pharmaceuticals|XFOR - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months x4pharma.com|XFOR - Earnings growth in current year|Earnings growth forecast for next year X4 Pharmaceuticals
Initial company analysis:X4 Pharma (XFOR)
For X4 Pharmaceuticals (XFOR), success depends on the market adoption of WHIM syndrome therapy and insurance coverage, which is directly reflected in the Enterprise Value to EBITDA multiple. This ratio relates total capitalization and debt to operating profit before taxes, allowing investors to assess the real value of the business by filtering out market noise and avoiding overpaying for the asset amid volatile earnings.
Competitor analysis for X4 Pharmaceuticals
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA: Enterprise Value to EBITDA Ratio|DNTH (Dianthus Corp) - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Operating Income Before Depreciation Pharvaris N.V.|Enterprise Value to EBITDA Ratio AbCellera|TRML - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PGEN|PHAR - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple Nektar Corp (NKTR)|Business Value to Operating Income Before Depreciation Upstream Bio Inc|EV/EBITDA Multiple zenasbio.com ZBIO|Immunome - EV/EBITDA Multiple|GOSS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation KalVista Pharmaceuticals Inc KALV|SEPN (Septerna Pharma) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio PVLA|EV/EBITDA Multiple savarapharma.com|EV/EBITDA Multiple RIGL|EV/EBITDA Multiple AnaptysBio Inc (ANAB)|Astria Pharma - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple enGene Corp ENGN|RAPT (RAPT Therapeutics) - Company Value to EBITDA|Aerovate Therapeutics Inc (JBIO) - Enterprise Value to EBITDA Ratio|ACRS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Kyverna Therapeutics Inc.|Tiziana Life Sciences PLC (TLSA) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple Cabaletta Bio Inc|VTYX (Ventyx Biosciences) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple theratech.com (THTX)|Avalo Therapeutics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Eledon Pharmaceuticals Inc. ELDN|Agenus Inc - EV/EBITDA Multiple|CLYM: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Zura Bio (ZURA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ATYR (atyrpharma.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADAG: Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio Ikena Oncology, Inc. (IMA)|Enterprise Value to Operating Income Before Depreciation Shattuck Labs, Inc. STTK|EV/EBITDA Multiple equilliumbio.com (EQ)|Connect Biopharma Holdings Limited (CNTB) - Company Value to Operating Income Before Depreciation Ratio|Immunic Therapeutics - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ATRA (Atara Biotherapeutics Inc) - Company Value to EBITDA|IFRX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation adicetbio.com ACET|CELU (Celularity) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio INmune Bio, Inc. INMB|EV/EBITDA Multiple barinthusbio.com|Kezar Life Sciences, Inc. (KZR) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SAB Biotherapeutics Inc. (SABS)|EV/EBITDA Multiple AKTX (Akari Therapeutics plc)|Enlivex Therapeutics Ltd - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation Q32 Bio Corp (QTTB)|GOVX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|EDSA (Edesa Biotech) - Enterprise Value to EBITDA Ratio|iBio Inc (IBIO) - EV/EBITDA Multiple|CARM (Carisma Therapeutics Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio XTL Bio (XTLB)|Bolt Biotherapeutics (BOLT) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple hcwbiologics.com (HCWB)|Total Company Value to Operating Income Before Depreciation Ratio APVO|aimimmuno.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADTX: Enterprise Value to EBITDA Ratio|GRI: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XRTX (XORTX Therapeutics Inc.) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio reshapelifesciences.com|REVB (Revelation Biosciences, Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INDP|Enterprise Value to Operating Income Before Depreciation Scinai SCNI|EV/EBITDA Multiple calcimedica.com (CALI)|AFMD: Company Value to EBITDA|ALLK - Enterprise Value to EBITDA Ratio|HOOKIPA (HOOK) - Enterprise Value to Operating Income Before Depreciation|IGMS (IGM Biosciences, Inc.) - Enterprise Value to Operating Income Before Depreciation|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Ocean Biomedical Corp - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|thirdharmonicbio.com - Company Value to Operating Income Before Depreciation Ratio
